Kinfo
Immuron Ltd. Sponsored ADR logo

Immuron Ltd. Sponsored ADR

IMRNNASDAQHealthcare·US · USD
$1.07
-0.02 (-1.83%)
Prices as of October 5, 2026 · market closed

Price

Key statistics

Valuation
Market cap8.64M USD
Enterprise value-21.32K USD
Trailing P/E-2.08
Forward P/E-109.00
PEG ratio-109.00
Price / sales1.14
Price / book1.12
Profitability
Gross margin0.00%
Operating margin-45.12%
Profit margin-47.71%
Return on assets-19.14%
Return on equity-38.27%
Income (TTM)
Revenue5.37M USD
Gross profit3.46M USD
EBITDA-2.45M USD
Net income-2.56M USD
Diluted EPS-$0.34
Rev. growth (YoY)7.20%
Balance sheet
Total cash6.27M USD
Total debt131.84K USD
Debt / equity1.70
Current ratio7.26
Book value / share$0.97
Cash flow (TTM)
Operating cash flow-2.27M USD
Levered free cash flow-1.44M USD
Shares & price
Shares outstanding326.65M
Float7.14M
Held by institutions0.97%
Beta0.52
50-day MA$1.20
200-day MA$1.01
52-week high$2.39
52-week low$0.68
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-01-281.031.03+0.00%2025-11-111.321.32+0.00%2022-09-08—-0.01—2022-02-24—-0.01—2021-08-30—-0.03—
About Immuron Ltd. Sponsored ADR

Immuron Ltd. Sponsored ADR is the U.S.-listed depositary receipt for Immuron Limited, an Australian biopharmaceutical company focused on developing and commercializing oral polyclonal antibody products. Immuron’s current portfolio centers on products and programs designed for gastrointestinal and infectious disease applications, including Travelan, an over-the-counter product used to help reduce the risk of traveler’s diarrhea, and Protectyn, an immune supplement marketed for digestive health support. The company also maintains a research and development pipeline built around targeted antibody technologies and clinical-stage candidates for enteric and other gut-mediated conditions. Through its commercial products and clinical programs, Immuron participates in both consumer health and specialty biopharmaceutical markets, serving as a niche player in microbiome-linked and immune-focused therapies.

Sector
Healthcare
Industry
Biotechnology
Employees
7
Headquarters
Carlton, VIC, Australia

Frequently asked questions about Immuron Ltd. Sponsored ADR